DOCM Stock Analysis: DocMorris | SW
Pharmaceutical Retailers | SW, Switzerland | Market Cap: 420m CHF | 12M Return: 34.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.26M
Qual. Beats: 0
Rev. Trend: -41.4%
Warnings
Tailwinds
Seasonality 9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
DocMorris AG is a Swiss online pharmacy, telemedicine, and healthcare company active in Switzerland and internationally. Its offering includes prescription and over-the-counter medicines, consumer health, beauty and personal care products, nutritional supplements, painkillers, and first aid products. The company also provides professional services to doctors, pharmacies, insurers, and health institutions, distributing under the DocMorris, PromoFarma by DocMorris, and TeleClinic brands. Founded in 1993 and previously known as Zur Rose Group AG, the company adopted its current name in May 2023 and is headquartered in Frauenfeld, Switzerland.
Operating within the GICS Drug Retail sub-industry of the Consumer Staples sector, the company combines a mail-order pharmacy model with B2B services to insurers and health institutions, alongside its TeleClinic telemedicine platform. This hybrid retail-plus-services structure is characteristic of European online pharmacy operators, which have expanded as regulators across the EU and Switzerland have formalized frameworks for the online dispensing of prescription medicines.
- German e-prescription adoption accelerates mail-order prescription volume
- Swiss regulators tighten mail-order pharmacy prescription rules
- Persistent operating losses trigger restructuring and cost reduction
| Net Income: -218.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.11 > 0.02 and ΔFCF/TA 3.97 > 1.0 |
| NWC/Revenue: 8.32% < 20% (prev 6.45%; Δ 1.87% < -1%) |
| CFO/TA -0.05 > 3% & CFO -39.6m > Net Income -218.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.6m) vs 12m ago 115.8% < -2% |
| Gross Margin: 10.45% > 18% (prev 16.18%; Δ -5.73% > 0.5%) |
| Asset Turnover: 240.2% > 50% (prev 193.3%; Δ 46.90% > 0%) |
| Interest Coverage Ratio: -8.92 > 6 (EBIT TTM -157.6m / Interest Expense TTM 17.7m) |
| A: 0.19 (Total Current Assets 294.8m - Total Current Liabilities 134.5m) / Total Assets 825.4m |
| B: -0.88 (Retained Earnings -728.3m / Total Assets 825.4m) |
| C: -0.20 (EBIT TTM -157.6m / Avg Total Assets 801.8m) |
| D: 0.98 (Book Value of Equity 409.1m / Total Liabilities 416.3m) |
| Altman-Z'' = -1.89 = D |
| DSRI: 0.92 (Receivables 82.3m/69.8m, Revenue 1.93b/1.50b) |
| GMI: 1.55 (GM 16.18% / 10.45%) |
| AQI: 0.90 (AQ_t 0.59 / AQ_t-1 0.66) |
| SGI: 1.28 (Revenue 1.93b / 1.50b) |
| TATA: -0.22 (NI -218.9m - CFO -39.6m) / TA 825.4m) |
| Beneish M = -2.48 (Cap -4..+1) = BBB |
As of July 14, 2026, the stock is trading at CHF 10.06 with a total of 1,509,317 shares traded. Over the past week, the price has changed by +10.67%, over one month by +26.54%, over three months by +78.69% and over the past year by +34.13%.
Current recommended Stop Loss: 9.50 (which is 5.6% or 1.3 ATR below the current price).
DocMorris has no consensus analysts rating.
P/S = 0.3738
P/B = 0.8858
Revenue TTM = 1.93b CHF
EBIT TTM = -157.6m CHF
EBITDA TTM = -112.7m CHF
Long Term Debt = 248.1m CHF (from longTermDebt, last quarter)
Short Term Debt = 26.4m CHF (from shortTermDebt, last quarter)
Debt = 313.2m CHF (from shortLongTermDebtTotal, last quarter) + Leases 24.6m
Net Debt = 193.3m CHF (calculated: Debt 313.2m - CCE 119.9m)
Enterprise Value = 613.6m CHF (420.3m + Debt 313.2m - CCE 119.9m)
Interest Coverage Ratio = -8.92 (Ebit TTM -157.6m / Interest Expense TTM 17.7m)
EV/FCF = -6.82x (Enterprise Value 613.6m / FCF TTM -90.0m)
FCF Yield = -14.67% (FCF TTM -90.0m / Enterprise Value 613.6m)
FCF Margin = -4.67% (FCF TTM -90.0m / Revenue TTM 1.93b)
Net Margin = -11.37% (Net Income TTM -218.9m / Revenue TTM 1.93b)
Gross Margin = 10.45% ((Revenue TTM 1.93b - Cost of Revenue TTM 1.72b) / Revenue TTM)
Gross Margin QoQ = -2.61% (prev 22.34%)
Tobins Q-Ratio = 0.74 (Enterprise Value 613.6m / Total Assets 825.4m)
Interest Expense / Debt = 5.64% (Interest Expense 17.7m / Debt 313.2m)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = -118.2m (EBIT -157.6m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 2.19 (Total Current Assets 294.8m / Total Current Liabilities 134.5m)
Debt / Equity = 0.77 (Debt 313.2m / totalStockholderEquity, last quarter 409.1m)
Debt / EBITDA = -1.71 (negative EBITDA) (Net Debt 193.3m / EBITDA -112.7m)
Debt / FCF = -2.15 (negative FCF - burning cash) (Net Debt 193.3m / FCF TTM -90.0m)
Total Stockholder Equity = 386.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.31% (Net Income -218.9m / Total Assets 825.4m)
RoE = -56.64% (Net Income TTM -218.9m / Total Stockholder Equity 386.5m)
RoCE = -24.84% (EBIT -157.6m / Capital Employed (Equity 386.5m + L.T.Debt 248.1m))
RoIC = -19.04% (negative operating profit) (NOPAT -118.2m / Invested Capital 621.1m)
WACC = 5.98% (E(420.3m)/V(733.5m) * Re(7.28%) + D(313.2m)/V(733.5m) * Rd(5.64%) * (1-Tc(0.25)))
Discount Rate = 7.28% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 77.78 | Cagr: 93.54%
[DCF] Fair Price = unknown (Cash Flow -90.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: -41.39 | Revenue CAGR: -6.26% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=-1.78 | Chg30d=-0.02% | Revisions=-25% | GrowthEPS=+48.2% | GrowthRev=+8.5%
EPS next Year (2027-12-31): EPS=-1.11 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+37.6% | GrowthRev=+12.4%
[Analyst] Revisions Ratio: -12% (up=2, down=3)